As a former CEO-in-Residence with BioEnterprise, Glen Gaughan advised and supported biopharmaceutical companies, including BioMotiv, a therapeutic development company associated with the Harrington Project for Discovery & Development. In 2015, Gaughan joined BioMotiv where he now advances a portfolio of discoveries from research institutions to therapeutics for patients. Prior to BioEnterprise, Gaughan spent nearly 20 years as a drug discovery scientist with Bristol-Myers Squibb. In roles ranging from Principal Investigator to Group Leader, he contributed to programs searching for new medications for pain, obesity, sleep disorders, and depression, and for contrast agents for MRI. Gaughan designed ProHance, an MRI contrast agent marketed by Bracco. Gaughan holds a Ph.D. in Chemistry from the University of Oregon, an M.B. A from Case Western Reserve University, and a B.A. from Dartmouth.